Johnson & Johnson (J&J) announces positive results from a Phase 3 study for Tremfya in treating Crohn's disease. The study achieved all primary and secondary endpoints, highlighting the drug's potential as an IL-23 inhibitor. J&J has submitted an application to the U.S. FDA seeking approval for Tremfya in treating moderately to severely active Crohn's disease. Additionally, J&J has acquired an immune disease biologics company for $850 million.
J&J acquires immune disease biologics company for $850M https://t.co/52zXZefRvy
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's disease $JNJ https://t.co/4bLvblNxhH
J&J's subcutaneous version of Tremfya excels in Crohn's disease study https://t.co/IT2f8Rw8xp
We announced positive topline results from a Phase 3 study in adult patients with moderately to severely active Crohn’s disease (CD). Learn more about what this innovative research means for CD patients: https://t.co/le7ngieUkE #JNJImmunology https://t.co/2RHN42SERG
TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction $JNJ https://t.co/E8Hmo6dC2d
J&J: TREMFYA PHASE 3 CROHN'S DISEASE STUDY ACHIEVES ALL PRIMARY AND SECONDARY ENDPOINTS